Patient commentary : the current model has failed
Menée à partir de l'analyse de rapports réglementaires ou scientifiques portant sur 48 anticancéreux autorisés pour 68 indications par l'Agence Européenne du Médicament entre 2009 et 2013, cette étude évalue les bénéfices, en termes de survie ou de qualité de vie, associés à l'utilisation de ces médicaments
The cost of cancer drugs is skyrocketing: prices of cancer drugs increased by 10% every year between 1995 and 2013.1 More and more we’re seeing cancer drugs being priced off the NHS—as is the case with secondary breast cancer drug palbociclib, currently under review after it was rejected by NICE earlier this year because of cost.Another really hard burden to bear for patients is that so many …
BMJ , commentaire en libre accès, 2016